Logo Logo

Publications by Kessler, Mirjana

Up a level
Export as [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date
Number of items: 3.

Journal article

Chelariu-Raicu, Anca ORCID: 0000-0003-2944-9488; Holley, Eva; Mayr, Doris; Klauschen, Frederick; Wehweck, Fabienne; Rottmann, Miriam; Kessler, Mirjana; Kaltofen, Till; Czogalla, Bastian; Trillsch, Fabian ORCID: 0000-0002-1860-4350; Mahner, Sven ORCID: 0000-0002-2224-5709; Schmoeckel, Elisa ORCID: 0000-0001-7199-3837 (2022): A combination of immunohistochemical markers, MUC1, MUC5AC, PAX8 and growth pattern for characterization of mucinous neoplasm of the ovary. In: International Journal of Gynecologic Cancer, Vol. 32, No. 5: pp. 662-668

Ruscito, Ilary; Castillo-Tong, Dan Cacsire; Vergote, Ignace; Ignat, Iulia; Stanske, Mandy; Vanderstichele, Adriaan; Glajzer, Jacek; Kulbe, Hagen; Trillsch, Fabian; Mustea, Alexander; Kreuzinger, Caroline; Panici, Pierluigi Benedetti; Gourley, Charlie; Gabra, Hani; Nuti, Marianna; Taube, Eliane T.; Kessler, Mirjana; Sehouli, Jalid; Darb-Esfahani, Silvia; Braicu, Elena Ioana (2018): Characterisation of tumour microvessel density during progression of high-grade serous ovarian cancer: clinico-pathological impact (an OCTIPS Consortium study). In: British Journal of Cancer, Vol. 119, No. 3: pp. 330-338

Ruscito, Ilary; Castillo-Tong, Dan Cacsire; Vergote, Ignace; Ignat, Iulia; Stanske, Mandy; Vanderstichele, Adriaan; Ganapathi, Ram N.; Glajzer, Jacek; Kulbe, Hagen; Trillsch, Fabian; Mustea, Alexander; Kreuzinger, Caroline; Panici, Pierluigi Benedetti; Gourley, Charlie; Gabra, Hani; Kessler, Mirjana; Sehouli, Jalid; Darb-Esfahani, Silvia; Braicu, Elena Ioana (2017): Exploring the clonal evolution of CD133/aldehyde-dehydrogenase-1 (ALDH1)-positive cancer stem-like cells from primary to recurrent high-grade serous ovarian cancer (HGSOC). A study of the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium. In: European Journal of Cancer, Vol. 79: pp. 214-225

This list was generated on Sun Jan 29 23:48:18 2023 CET.